Invesaro

Stocks Health care CNBX

OTC · Health care

CNBX Pharmaceuticals Inc. (CNBX)

CNBX Pharmaceuticals Inc. brought in $0 of revenue over the twelve months to May 31, 2026. It posted a net loss of $462.1K. At May 31, 2026 it held $9.5K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on June 24, 2026.

Watch CNBX in 60 seconds
Price
$0.00
0.00% on the day · September 25, 2026
52-week range $0.00 to $0.00
Market cap
$160.6K
Revenue (last 12 months)
$0

What CNBX Pharmaceuticals Inc. does

CNBX Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CNBX.

Revenue and profit by year

Revenue
FY17: $9.6K $9.6K FY17FY19: $9.8K $9.8K FY19FY20: $7.2K $7.2K FY20FY21: $0 $0 FY21FY22: $30K $30K FY22FY23: $410.2K $410.2K FY23FY24: $130.1K $130.1K FY24FY25: $0 $0 FY25
Net income
FY17: -$3.8M -$3.8M FY17FY19: $1.1M $1.1M FY19FY20: -$7.5M -$7.5M FY20FY21: -$3.2M -$3.2M FY21FY22: -$3.7M -$3.7M FY22FY23: -$3.7M -$3.7M FY23FY24: -$695.2K -$695.2K FY24FY25: -$314K -$314K FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$0-$271.7K-$314K$0.00n/a
2024$130.1K-$583.1K-$695.2K-$0.02n/a
2023$410.2K-$931.4K-$3.7M-$0.42n/a
2022$30K-$3M-$3.7M-$3.59n/a
2021$0-$2.6M-$3.2M-$0.02n/a
2020$7.2K-$3M-$7.5M-$0.10n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 30, 2026.

Estimated from its filing rhythm: 52 weeks after its report of December 1, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What CNBX Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
  2. June 24, 2026
    Quarterly report 10-Q · period to May 31, 2026Diluted EPS $0.00 versus $0.00.
  3. May 8, 2026
  4. April 14, 2026
    Quarterly report 10-Q · period to February 28, 2026Diluted EPS $0.00 versus $0.00.
  5. March 17, 2026
  6. February 5, 2026
  7. January 14, 2026
    Quarterly report 10-Q · period to November 30, 2025Diluted EPS $0.00 versus -$0.00.
  8. December 1, 2025
    Annual report 10-K · period to August 31, 2025Diluted EPS $0.00 versus -$0.02.
  9. November 10, 2025
  10. August 13, 2025

Recent insider filings (Forms 3, 4 and 144): 10, the latest on February 4, 2019. Insider transactions on SEC

Who owns CNBX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
3i, LP13G, passive with 2 related filers 9.9% 169,341,400 August 14, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CNBX

What does CNBX Pharmaceuticals Inc. do?

CNBX Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CNBX.

Is CNBX Pharmaceuticals Inc. profitable?

No. Over the twelve months to May 31, 2026 it reported a net loss of $462.1K.

How much revenue does CNBX Pharmaceuticals Inc. make?

Over the twelve months to May 31, 2026 CNBX Pharmaceuticals Inc. reported revenue of $0.

When did CNBX Pharmaceuticals Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on June 24, 2026. It covers the period to May 31, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.

Similar companies

Compare CNBX with

Compare CNBX with any company

Follow CNBX

Get an email when CNBX Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CNBX: get an email when it files

Where the numbers come from

Financial figures are the values CNBX Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.